Saxagliptin Cost Without Insurance (2026): Onglyza, Kombiglyze & Generic Status

By Vincent Couey, RxGrab founder. Pricing cross-checked against Drugs.com, GoodRx, the FDA Orange Book, and manufacturer pages. Updated May 30, 2026.

Saxagliptin is the kind of drug that quietly punishes the uninsured. It is not a headline specialty biologic costing thousands a month, and it is not a $4 generic either. It sits in an awkward middle: a brand-only DPP-4 inhibitor with no marketed generic, priced like a brand because the market still gives it no other choice. If you are paying cash, that distinction is the whole story, and most cost guides get the generic status flat wrong. This page fixes that with verified figures and a clear path.

What is saxagliptin, and what does it cost?

Saxagliptin is a DPP-4 inhibitor, an oral medication for type 2 diabetes sold under the brand name Onglyza by AstraZeneca, and in a fixed-dose combination with extended-release metformin as Kombiglyze XR. DPP-4 inhibitors work by blocking dipeptidyl peptidase-4, which prolongs the body's own incretin hormones and improves blood-sugar control with a low risk of hypoglycemia. It is taken once daily, which makes it a convenient maintenance drug, and an expensive one if your plan does not cover it.

The cash math is blunt. Brand Onglyza runs about $529 for a 30-tablet supply of the 2.5 mg strength at cash retail, per the Drugs.com price guide accessed 2026-05-30. The 5 mg strength sits in a similar range, broadly $500 to $525 for 30 tablets. At roughly $529 a month, an uninsured patient is looking at more than $6,300 a year in OOP cost for a single once-daily pill. That is the number a savings plan has to beat, and there is no generic cash price to quote because no generic is marketed.

All figures are time- and location-variable. Treat each as "approximately, as of the date shown, verify current" rather than a guaranteed quote.

Is there a generic for Onglyza in 2026?

The honest answer is no, not a marketed one. As of May 30, 2026, there is no saxagliptin generic for sale in the United States, and this is the single most important correction this guide makes. The FDA has granted tentative approval to several generic filers who submitted an ANDA, with reporting placing Glenmark among roughly five filers, but a tentative approval is not permission to sell. It means the FDA judged the product to meet its standards but that patent or exclusivity protections still block the launch.

You can confirm this yourself. The FDA Orange Book, maintained by the Center for Drug Evaluation and Research (CDER), lists approved drug products and their approval status, including tentative approvals and patent listings, and it is the authoritative place to check before trusting any blog that claims a saxagliptin generic is available. Brand-side resources are blunt about the present state: Drugs.com still states that no generic is currently available and warns that one "may not be available for several years."

How much does Kombiglyze XR cost, and is it different?

Kombiglyze XR is a fixed-dose combination of saxagliptin plus extended-release metformin in a single once-daily tablet. Like Onglyza, it has no marketed generic as of 2026, so it is priced as a brand drug. That creates a quirk worth raising with your prescriber: metformin on its own is one of the cheapest generics in American pharmacies, frequently under $10 a month and on many $4 generic lists. The branded combination, by contrast, carries the full brand price because of the saxagliptin component bound into it.

For some patients, separate cheap generic metformin taken alongside a different, generically available antidiabetic can cost dramatically less than the branded Kombiglyze XR combination, while delivering comparable glucose control. That is a clinical decision, not a pricing one, so it belongs with your prescriber. But it is the kind of question that routinely saves cash-pay patients hundreds of dollars a month, and almost nobody is told to ask it. If you are weighing combining medications, verify there are no harmful interactions first; the cross-tradition interaction tools at OmniRx cover DPP-4 inhibitor and metformin interactions in detail.

Which cash-pay levers actually work for saxagliptin?

A savings lever is any mechanism that lowers what you actually pay at the counter. For a brand-only drug with no generic, the set of working levers is narrower than for a commodity generic, and one popular lever is a trap for the uninsured. Here is the honest ranking for a cash-pay patient.

1. Discount coupons, GoodRx or SingleCare. Free, cash-pay, and require no insurance. A brand Onglyza coupon is commonly cited near $48 to $67, but coupon prices move with pharmacy, ZIP code, and date, so treat that as "around this much, verify current" and price it live at GoodRx before you go. This is usually the single biggest cut available for the brand product.
2. Patient assistance program, AstraZeneca. Manufacturer- and foundation-run programs provide free or low-cost medication to low-income and uninsured patients, subject to income eligibility. Unlike copay cards, a patient assistance program can serve cash-pay and uninsured payers, which makes it the best lever for a high-cost brand drug when no affordable generic exists. Our patient assistance programs guide walks through the application.
3. 90-day supply. For a stable maintenance dose, a 90-day fill lowers per-month cost and cuts repeat dispensing fees. It does not change the unit price, but it trims the overhead on a chronic medication.
4. Therapeutic or in-class switch. Ask your prescriber whether a DPP-4 inhibitor with a marketed generic, or a different antidiabetic class that has cheap generics, fits your treatment plan. This is the lever that can erase the cost entirely, and it is a clinical conversation, not a coupon.

Note one lever that does not work here. Mark Cuban's Cost Plus Drugs is excellent for established generics, where its transparent model of manufacturer cost plus a 15 percent markup plus a pharmacy fee and shipping produces remarkable prices on drugs like atorvastatin or pitavastatin calcium. But it cannot manufacture a generic that does not exist. Because there is no marketed saxagliptin generic in 2026, Cost Plus cannot deliver a cheap saxagliptin. Verify live availability at costplusdrugs.com, but set expectations accordingly.

Where does saxagliptin sit among brand-drug near-misses?

A "brand-drug near-miss" is a drug whose cash price is painful today but whose category shows what relief looks like once a generic arrives. Saxagliptin is a textbook example, and the contrast with drugs that have already crossed the generic line is stark. The chart below plots representative cash prices on a logarithmic scale, because the gap between a brand specialty drug and its generic is so large it does not fit a linear axis.

Read the chart top to bottom and the lesson is plain. Teriflunomide (brand Aubagio), an oral disease-modifying therapy for relapsing multiple sclerosis (MS), runs roughly $8,000 to $9,300 a month as a brand, yet its marketed generic lands near $28 to $40 with a coupon, per GoodRx and SingleCare pricing, a saving above 99 percent. Dimethyl fumarate (brand Tecfidera), another oral MS therapy near $7,800 a month as a brand, drops to roughly $41 and up as a marketed generic. Pitavastatin calcium, the high-cost statin sold as brand Livalo near $237 a month, falls to around $37 with a coupon as a generic, and is carried on Cost Plus Drugs. And the everyday high-intensity statins, atorvastatin and rosuvastatin, sit near $6 to $10 a month as long-established generics.

Saxagliptin is the one row on that chart with no second bar. Every other drug shows what the cash price becomes once a generic competes; saxagliptin shows only the brand. That is precisely why it is a near-miss: the relief is structurally available, it has simply not arrived. Once a marketed saxagliptin generic launches, this article will be updated, because the price could move from the $500 range toward the low double digits the way pitavastatin and the statins already have.

How should you decide your saxagliptin path?

A decision path is just the cash-pay ranking applied to your actual situation. Work it top to bottom and stop at the first option that fits.

1. Are you uninsured with low income? Apply to the AstraZeneca patient assistance program first. If approved, your cost can fall to little or nothing, and this beats every coupon. Income documentation and a prescriber signature are typically required.
2. Are you above the assistance income threshold? Run a brand Onglyza coupon at GoodRx or SingleCare and price it at several pharmacies. The commonly cited $48 to $67 range is realistic for the brand, but verify it live because coupon prices move.
3. Is the cost still too high? Ask your prescriber about a DPP-4 inhibitor that has a marketed generic, or another antidiabetic class with cheap generics. A clinical switch is the only lever that can erase the cost rather than discount it.
4. On a stable dose? Move to a 90-day supply to trim per-month cost and dispensing fees.
5. Tempted to wait for the generic? Do not stop or skip doses to wait. There is no marketed generic yet and the timeline is uncertain. Bridge with a coupon or assistance now, and re-check the Orange Book periodically.

If your costs are driven by other high-priced brand or specialty drugs alongside saxagliptin, the enrollment and assistance mechanics in our specialty pharmacy guide apply to the whole basket, not just one molecule. And if you want the science behind DPP-4 inhibitors and where they fit in type 2 diabetes management, Health Britannica covers the incretin pathway and oral diabetes drug classes in depth.

Frequently asked questions